Omidubicel as Adjunct Treatment for Hematologic Malignancies
Customize your policy alerts
Sign up for Bluecross Idaho Policy 8.01.568 alerts
Get alerted when Policy 8.01.568 changes without checking for updates manually.
Monitor payer policy activity
Coverage policy addressing omidubicel for individuals with hematologic malignancies planning myeloablative allogeneic umbilical cord blood transplantation; use in this setting is considered investigational.
The policy was replaced on November 19, 2026, with updated references and no change to the policy statements.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.